Literature DB >> 9428781

Estrogen receptor expression in benign breast epithelium and breast cancer risk.

S A Khan1, M A Rogers, K K Khurana, M M Meguid, P J Numann.   

Abstract

BACKGROUND: Estrogen exposure is a major risk factor for breast cancer. Increased estrogen responsiveness of breast epithelium may enhance this effect. We examined the relationship between breast cancer diagnosis and 1) the presence and absence of estrogen receptor expression in benign breast epithelium, 2) the level of expression and 3) its variation during the menstrual cycle, and 4) other established risk factors. e.g., age, age at menarche, parity, and family history.
METHODS: We measured estrogen receptor expression (as % of positive cells) by immunohistochemistry in normal breast epithelium from 376 women undergoing diagnostic or therapeutic breast surgery. Data on established risk factors were collected prior to surgery and those on menstrual cycle dates at the time of surgery. Logistic regression was used to assess risks (odds ratios [ORs]).
RESULTS: The crude OR for breast cancer in women with estrogen receptor-positive breast epithelium versus those without was 3.16 (95% confidence interval [CI] = 1.89-5.28), with an OR of 2.49 (95% CI = 1.25-4.96) for premenopausal and an OR of 3.32 (95% CI = 1.43-7.68) for postmenopausal women. The ORs remained high and statistically significant after controlling for age and other breast cancer risk factors. The level of estrogen receptor expression was higher in patients with breast cancer than in control subjects and it was related to breast cancer risk in postmenopausal women (P trend <.005). Expression declined as expected in premenopausal control subjects as the menstrual cycle progressed but rose in breast cancer patients (P trend <.015).
CONCLUSIONS: The overexpression of estrogen receptors in normal breast epithelium may augment estrogen sensitivity and hence the risk of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9428781     DOI: 10.1093/jnci/90.1.37

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  70 in total

Review 1.  Apoptosis in the estrous and menstrual cycles.

Authors:  A C Andres; R Strange
Journal:  J Mammary Gland Biol Neoplasia       Date:  1999-04       Impact factor: 2.673

2.  Prepubertal exposure to cow's milk reduces susceptibility to carcinogen-induced mammary tumorigenesis in rats.

Authors:  Tina S Nielsen; Galam Khan; Jennifer Davis; Karin B Michels; Leena Hilakivi-Clarke
Journal:  Int J Cancer       Date:  2011-01-01       Impact factor: 7.396

Review 3.  Endocrine therapy resistance in breast cancer: current status, possible mechanisms and overcoming strategies.

Authors:  Weimin Fan; Jinjia Chang; Peifeng Fu
Journal:  Future Med Chem       Date:  2015-08-26       Impact factor: 3.808

4.  Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells.

Authors:  Olga Ch Kousidou; Aikaterini Berdiaki; Dimitris Kletsas; Alexandros Zafiropoulos; Achilleas D Theocharis; George N Tzanakakis; Nikos K Karamanos
Journal:  Mol Oncol       Date:  2008-06-18       Impact factor: 6.603

5.  Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.

Authors:  Karla Kerlikowske; Charlotte C Gard; Jeffrey A Tice; Elad Ziv; Steven R Cummings; Diana L Miglioretti
Journal:  J Natl Cancer Inst       Date:  2016-12-31       Impact factor: 13.506

6.  Evaluation of the kinetic properties of background parenchymal enhancement throughout the phases of the menstrual cycle.

Authors:  Alana R Amarosa; Jason McKellop; Ana Paula Klautau Leite; Melanie Moccaldi; Tess V Clendenen; James S Babb; Anne Zeleniuch-Jacquotte; Linda Moy; Sungheon Kim
Journal:  Radiology       Date:  2013-05-08       Impact factor: 11.105

7.  A randomized phase II presurgical trial of transdermal 4-hydroxytamoxifen gel versus oral tamoxifen in women with ductal carcinoma in situ of the breast.

Authors:  Oukseub Lee; Katherine Page; David Ivancic; Irene Helenowski; Vamsi Parini; Megan E Sullivan; Julie A Margenthaler; Robert T Chatterton; Borko Jovanovic; Barbara K Dunn; Brandy M Heckman-Stoddard; Kathleen Foster; Miguel Muzzio; Julia Shklovskaya; Silvia Skripkauskas; Piotr Kulesza; David Green; Nora M Hansen; Kevin P Bethke; Jacqueline S Jeruss; Raymond Bergan; Seema A Khan
Journal:  Clin Cancer Res       Date:  2014-07-15       Impact factor: 12.531

8.  Parity and expression of epithelial histopathologic markers in breast tissue.

Authors:  Yukiko Morimoto; Jeffrey Killeen; Brenda Y Hernandez; J Mark Cline; Gertraud Maskarinec
Journal:  Eur J Cancer Prev       Date:  2013-09       Impact factor: 2.497

9.  A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer.

Authors:  Dan Tian; Natalia M Solodin; Prashant Rajbhandari; Kelsi Bjorklund; Elaine T Alarid; Pamela K Kreeger
Journal:  FASEB J       Date:  2015-02-03       Impact factor: 5.191

Review 10.  Estrogen receptor alpha in human breast cancer: occurrence and significance.

Authors:  S Ali; R C Coombes
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-07       Impact factor: 2.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.